1. Volume 53, Issue 5, Pages 941-949 (May 2008)
Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891) 
Urs E. Studer, Laurence Collette, Peter Whelan, Walter Albrecht, Jacques Casselman, Theo de Reijke, Hartmut Knönagel, Wolfgang Loidl, Santiago Isorna, Subramanian K. Sundaram, Muriel Debois 
European Urology 
Volume 53, Issue 5, Pages (May 2008)
DOI: /j.eururo
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Overall and prostate cancer mortality of eligible patients in European Organization for Research and Treatment of Cancer (EORTC) trial who complied with the allocated treatment policy. Deferred–OS=overall mortality on deferred androgen-deprivation therapy (ADT) arm; Immediate–OS=overall mortality on immediate ADT arm. Deferred-PCa=prostate-cancer mortality on deferred ADT arm; Immediate-PCa=prostate cancer mortality on immediate ADT arm.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Cumulative incidence of prostate cancer mortality in the immediate (A) and deferred (B) androgen-deprivation therapy (ADT) arms according to baseline serum PSA. (A) Prostate cancer mortality in the immediate ADT arm according to baseline PSA. (B) Prostate cancer mortality in the deferred ADT arm according to baseline PSA.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
Cumulative incidence of prostate cancer mortality by treatment group in patients with baseline prostate-specific antigen (PSA)≤8ng/ml (A), 8.1–20ng/ml (B), 20.1–50ng/ml (C), and >50ng/ml (D). (A) Cumulative incidence of prostate cancer mortality, baseline PSA≤8ng/ml; (B) Cumulative incidence of prostate cancer mortality, baseline PSA 8.1–20ng/ml. (C) Cumulative incidence of prostate cancer mortality, baseline PSA 20.1–50ng/ml. (D) Cumulative incidence of prostate cancer mortality, baseline PSA>50ng/ml. ADT, androgen-deprivation therapy.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions

5. Fig. 4
Cumulative incidence and time from study entry to initiation of deferred androgen-deprivation therapy.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions

6. Fig. 5
Cumulative incidence of prostate cancer (A) and overall mortality (B) according to prostate-specific antigen doubling time (PSADT) in patients with a baseline PSA of 8.1–50ng/ml in the deferred androgen-deprivation therapy arm. (A) Cumulative incidence of prostate cancer mortality according to PSADT observed during the first 2 yr after study entry. The risk of PCa death was 7.5 times higher (95% confidence interval [95%CI], 3.3–17.2) for patients with a PSADT≤12 mo than for patients with a PSADT>12 mo. (B) Cumulative incidence of overall mortality according to PSADT time observed during the first 2 yr after study entry. The risk of overall mortality was 3.3 times higher (95%CI, 1.94–5.67) for patients with a PSADT≤12 mo than for patients with a PSADT>12 mo.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions

7. Fig. 6
Patients with a prostate-specific antigen (PSA) nadir≤2ng/ml after immediate androgen-deprivation therapy: (A) time to return to a PSA>2ng/ml, and (B) prostate cancer mortality according to baseline PSA. (A) Cumulative incidence of a return to a PSA>2ng/ml from a PSA nadir≤2ng/ml according to baseline PSA. (B) Cumulative incidence of prostate cancer mortality according to baseline PSA in patients with a PSA nadir≤2ng/ml.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions